Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Li-Ting Liu

Showing results (101-110 of 123) with videos related to

Pageof 13
Sort By:
Nature Communications|August 14, 2023
Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trialLi Yuan, Guo-Dong Jia, Xiao-Fei Lv, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 9, 2021
Nomogram for the prediction of primary distant metastasis of nasopharyngeal carcinoma to guide individualized application of FDG PET/CTBei-Bei Xiao, Da-Feng Lin, Xue-Song Sun, et al.
Cancer Research and Treatment|September 15, 2017
Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era: A Large-Scale Cohort StudyQiu-Yan Chen, Shao-Yan Guo, Lin-Quan Tang, et al.
European Radiology|January 8, 2021
Low value of whole-body dual-modality [18f]fluorodeoxyglucose positron emission tomography/computed tomography in primary staging of stage I-II nasopharyngeal carcinoma: a nest case-control studyBei-Bei Xiao, Qiu-Yan Chen, Xue-Song Sun, et al.
European Journal of Cancer (Oxford, England : 1990)|October 6, 2023
Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trialShan-Shan Guo, Jin-Hao Yang, Xue-Song Sun, et al.
International Journal of Radiation Oncology, Biology, Physics|December 9, 2014
High-sensitivity C-reactive protein complements plasma Epstein-Barr virus deoxyribonucleic acid prognostication in nasopharyngeal carcinoma: a large-scale retrospective and prospective cohort studyLin-Quan Tang, Chao-Feng Li, Qiu-Yan Chen, et al.
BMC Cancer|August 12, 2014
Elevated levels of plasma D-dimer predict a worse outcome in patients with nasopharyngeal carcinomaWen-Hui Chen, Lin-Quan Tang, Feng-Wei Wang, et al.
BMC Cancer|December 18, 2015
The impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with advanced-stage nasopharyngeal carcinoma in an era of intensity-modulated radiotherapyShan-Shan Guo, Lin-Quan Tang, Lu Zhang, et al.
BMC Cancer|February 2, 2018
Pretreatment quality of life as a predictor of survival for patients with nasopharyngeal carcinoma treated with IMRTShan-Shan Guo, Wen Hu, Qiu-Yan Chen, et al.
Oncotarget|April 23, 2016
Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched studyShan-Shan Guo, Lin-Quan Tang, Qiu-Yan Chen, et al.
Pageof 13

Showing results (101-110 of 123) with videos related to

Sort By:
Pageof 13
Nature Communications|August 14, 2023
Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trialLi Yuan, Guo-Dong Jia, Xiao-Fei Lv, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 9, 2021
Nomogram for the prediction of primary distant metastasis of nasopharyngeal carcinoma to guide individualized application of FDG PET/CTBei-Bei Xiao, Da-Feng Lin, Xue-Song Sun, et al.
Cancer Research and Treatment|September 15, 2017
Combination of Tumor Volume and Epstein-Barr Virus DNA Improved Prognostic Stratification of Stage II Nasopharyngeal Carcinoma in the Intensity Modulated Radiotherapy Era: A Large-Scale Cohort StudyQiu-Yan Chen, Shao-Yan Guo, Lin-Quan Tang, et al.
European Radiology|January 8, 2021
Low value of whole-body dual-modality [18f]fluorodeoxyglucose positron emission tomography/computed tomography in primary staging of stage I-II nasopharyngeal carcinoma: a nest case-control studyBei-Bei Xiao, Qiu-Yan Chen, Xue-Song Sun, et al.
European Journal of Cancer (Oxford, England : 1990)|October 6, 2023
Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trialShan-Shan Guo, Jin-Hao Yang, Xue-Song Sun, et al.
International Journal of Radiation Oncology, Biology, Physics|December 9, 2014
High-sensitivity C-reactive protein complements plasma Epstein-Barr virus deoxyribonucleic acid prognostication in nasopharyngeal carcinoma: a large-scale retrospective and prospective cohort studyLin-Quan Tang, Chao-Feng Li, Qiu-Yan Chen, et al.
BMC Cancer|August 12, 2014
Elevated levels of plasma D-dimer predict a worse outcome in patients with nasopharyngeal carcinomaWen-Hui Chen, Lin-Quan Tang, Feng-Wei Wang, et al.
BMC Cancer|December 18, 2015
The impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with advanced-stage nasopharyngeal carcinoma in an era of intensity-modulated radiotherapyShan-Shan Guo, Lin-Quan Tang, Lu Zhang, et al.
BMC Cancer|February 2, 2018
Pretreatment quality of life as a predictor of survival for patients with nasopharyngeal carcinoma treated with IMRTShan-Shan Guo, Wen Hu, Qiu-Yan Chen, et al.
Oncotarget|April 23, 2016
Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched studyShan-Shan Guo, Lin-Quan Tang, Qiu-Yan Chen, et al.
Pageof 13